CJC-1295 + Ipamorelin Blend combines two of the most widely investigated growth hormone secretagogues into a single synergistic formulation. By linking CJC-1295 No DAC (Modified GRF 1-29) and the selective ghrelin agonist Ipamorelin, the formulation allows investigators to study dual-pathway GHRH and GHS receptor stimulation on somatotropic cells in vitro.

"Dual receptor pathway activation via GHRH and GHS receptors produces a synergistic somatotropic release that exceeds the potential of single agonists."

Peer-reviewed literature on both components is indexable at PubMed at PubMed Secretagogue Blend Collection and related genomic targets cataloged at the NCBI Genomic Database. Preclinical models evaluate combined intracellular cAMP and calcium signaling surges.

Key Areas of Investigation:

• Dual-Pathway Receptor Synergism: Evaluating GHRHR and GHSR binding dynamics in vitro.
• Intracellular Signaling Cascades: Studies on cAMP and intracellular calcium surges in somatotropes.
• Anabolic Signal Induction: Preclinical research on secondary liver IGF-1 synthesis.

This material is supplied exclusively as a lyophilized solid for laboratory research and analytical evaluation, and is strictly not for human or therapeutic use.